Solventum (NYSE:SOLV) Hits New 52-Week High - Here's What Happened

Key Points

• Solventum shares hit a new 52-week high of $94.16 and last traded around $92.92, up from the prior close of $91.06.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus, with eight Buy, four Hold, and one Sell rating; several firms recently raised price targets as high as $101.
• Solventum beat quarterly expectations, reporting $2.55 in EPS on $2.21 billion in revenue, while revenue increased 2.2% year over year. Institutional investors, including California State Teachers Retirement System and Independent Franchise Partners, also increased their holdings.

Solventum Corporation (NYSE:SOLV - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $94.16 and last traded at $92.9160, with a volume of 60086 shares traded. The stock had previously closed at $91.06.

Analysts Set New Price Targets

SOLV has been the subject of a number of analyst reports. BTIG Research increased their price target on Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wedbush lifted their price objective on Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. Stifel Nicolaus upped their target price on Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Wells Fargo & Company reduced their target price on Solventum from $83.00 to $70.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $91.64.

Solventum Price Performance

The firm has a market capitalization of $15.67 billion, a price-to-earnings ratio of 11.26, a PEG ratio of 1.17 and a beta of 0.60. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The business has a 50-day moving average price of $82.81 and a two-hundred day moving average price of $75.61.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm posted $1.69 EPS. The business's revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts forecast that Solventum Corporation will post 7.22 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Independent Franchise Partners LLP increased its stake in shares of Solventum by 19.0% in the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock valued at $1,216,785,000 after purchasing an additional 2,456,451 shares during the period. California State Teachers Retirement System raised its holdings in shares of Solventum by 5,434.1% during the second quarter. California State Teachers Retirement System now owns 13,234,928 shares of the company's stock valued at $1,021,075,000 after buying an additional 12,995,776 shares during the last quarter. State Street Corp boosted its position in shares of Solventum by 2.0% during the fourth quarter. State Street Corp now owns 6,344,761 shares of the company's stock worth $502,759,000 after buying an additional 124,490 shares during the period. Boston Partners boosted its position in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company's stock worth $338,006,000 after buying an additional 959,543 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company's stock worth $362,375,000 after buying an additional 763,308 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source